Participants with complications (e.g. pressure sore, chest infection) at end of study · Older people undergoing hip fracture aftercare
Multinutrient supplements (oral) may leads to lower participants with complications (e.g. pressure sore, chest… compared with control (low certainty).
1 finding from 1 review
Disability (unfavourable outcomes: death, vegetative state, severe disability; GOS 1‐3) at end of scheduled · Older people undergoing hip fracture aftercare
It is very uncertain whether multinutrient supplements (oral) changes unfavourable outcome 7 by end of study compared with control (very low certainty).
1 finding from 1 review
Putative side effects of treatment (e.g. vomiting and diarrhoea) · Older people undergoing hip fracture aftercare
It is very uncertain whether multinutrient supplements (oral) changes putative side effects of treatment (e.g. vomiting and diarrhoea) compared with control (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review
Four of the participants withdrew from the study by Kimos et al 2007 due to adverse effects, but neither the type of adverse effect nor the trial group was specified.
1 study · 44 participants
GRADE not reported
Participants' assessment of improvement of pain in right TMJ (VAS) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
Oral clonazepam (benzodiazepine) showed no clear difference in participants' assessment of improvement of pain in right TMJ (VAS) compared with placebo; GRADE not reported.
1 finding from 1 review
Pain on palpation of right masseter muscle (VAS) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
Oral clonazepam (benzodiazepine) showed no clear difference in pain on palpation of right masseter muscle (VAS) compared with placebo; GRADE not reported.
1 finding from 1 review
Participants' assessment of global function (VAS) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
Oral gabapentin (anticonvulsant) showed no clear difference in participants' assessment of global function (VAS) compared with placebo; GRADE not reported.
1 finding from 1 review
Number of tender sites on muscles of mastication (palpation index) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
Oral gabapentin (anticonvulsant) led to lower number of tender sites on muscles of mastication (palpation index) compared with placebo; GRADE not reported.
1 finding from 1 review
Spontaneous pain in the TMJ (VAS) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
Oral gabapentin (anticonvulsant) led to lower spontaneous pain in the TMJ (VAS) compared with placebo; GRADE not reported.
1 finding from 1 review
Jaw pain (VAS) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
Oral clonazepam (benzodiazepine) showed no clear difference in jaw pain (VAS) compared with placebo; GRADE not reported.
1 finding from 1 review
Participants' assessment of improvement of pain in left TMJ (VAS) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
Oral clonazepam (benzodiazepine) showed no clear difference in participants' assessment of improvement of pain in left TMJ (VAS) compared with placebo; GRADE not reported.
1 finding from 1 review
Pain on palpation of left masseter muscle (VAS) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
Oral clonazepam (benzodiazepine) showed no clear difference in pain on palpation of left masseter muscle (VAS) compared with placebo; GRADE not reported.
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
Oral celecoxib (COX-2 inhibitor) showed no clear difference in pain intensity (VAS) compared with placebo; GRADE not reported.
1 finding from 1 review
Adverse events (reported; mild, no withdrawals) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review
Ta and Dionne 2004 (celecoxib) reported adverse effects. Per the review: 'All but one study (Lobo et al 2004) reported adverse effects. Most of the reported adverse effects were mild and similar to the adverse effects…
1 study · 68 participants
GRADE not reported
Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review
Death at final · primary membranous nephropathy in adults with nephrotic syndrome
Oral alkylating agents ± steroids showed no clear difference in death at final compared with placebo/no treatment/steroids (low certainty).
1 finding from 1 review
End‐stage renal disease · primary membranous nephropathy in adults with nephrotic syndrome
Oral alkylating agents ± steroids probably leads to lower end‐stage kidney disease at final compared with placebo/no treatment/steroids (moderate certainty).
1 finding from 1 review
Total remission (complete or partial) at final · primary membranous nephropathy in adults with nephrotic syndrome
Oral alkylating agents ± steroids probably leads to higher total remission (complete or partial) at final compared with placebo/no treatment/steroids (moderate certainty).
1 finding from 1 review
Complete remission · primary membranous nephropathy in adults with nephrotic syndrome
Oral alkylating agents ± steroids probably leads to higher complete remission at final compared with placebo/no treatment/steroids (moderate certainty).
1 finding from 1 review
Relapse · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether oral alkylating agents ± steroids changes recurrence of disease (relapse) at final compared with placebo/no treatment/steroids (very low certainty).
1 finding from 1 review